Explorez tous les épisodes du podcast Cell Mates

What does it take to build the infrastructure that helps robotics teams understand, debug, and improve increasingly complex systems?

In this special founder’s episode of Cell Mates, the format is flipped: Adrian MacNeil, Co-Founder and CEO of Foxglove, interviews Fred Parietti, Co-Founder and CEO of Multiply Labs.

Highlights include:

• The founder journey behind building companies at the frontier of robotics infrastructure and biological manufacturing.
• What robotics companies need to scale from development into real-world deployment
• How robotics and automation could reshape the future of pharmaceutical manufacturing

This episode offers a candid look at the technical and strategic challenges behind building dependable robotic systems - and the infrastructure required to support them.

New to Cell Mates? We’re the podcast where pharma, robotics, and automation collide to reimagine the future of medicine - one operation at a time.

What actually makes automation “stick” in cell therapy manufacturing? Is it the tech… or the trust?

In Episode 4 of Cell Mates, Fred sits down with Mary-Ann Santos from Thermo Fisher Scientific to unpack the real adoption flywheel: belief, fear, data, and the moment everything clicks when you see a robot run a process with your own eyes.

They go deep on why modular automation scales faster than “all-in-one” systems, how instrument design can make or break robotics integration, and why the most regulated environments are often the ones where robots shine the brightest (repeatability + sterility, plus, yes, robots don’t breathe).

Highlights include:

• The adoption flywheel: what speeds automation up (and what slows it down)
• Why data beats vibes: building confidence with peer-reviewed performance + demos
• Modular vs all-in-one systems: throughput, bottlenecks, and future-proofing
• “Robot-friendly” instruments: what makes automation easy vs painful
• GMP, sterility, and why humans (lovingly) are a contamination risk
• The next decade: decentralized manufacturing… and what still has to be true for GMP

This episode is about one thing: getting therapies to patients faster without blowing up quality, process trust, or regulatory reality.

New to Cell Mates? We’re the podcast where pharma, robotics, and automation collide to reimagine the future of medicine—one operation at a time.

What is a collaborative robot, and what makes it special? Why does this characteristic make it suitable for the pharma space?

In Episode 3 of Cell Mates, we explore how collaborative robotics could redefine manufacturing models, shift the role of human experts, and unlock entirely new possibilities in biomanufacturing.

Highlights include:

• What other industries can teach pharma about robotic adoption
  
  
• How to build trust in automation within highly regulated environments
  
  
• The “moonshot projects” that could change everything

This episode breaks down the future we’re building!

New to Cell Mates? We’re the podcast where pharma, robotics, and automation collide to reimagine the future of medicine - one operation at a time.

What tasks are humanoids uniquely good at and what does that mean for the future of work?

In Episode 2 of Cell Mates, we invite Tony Yang, Director of North American Markets from Unitree Robotics to discuss the future of humanoid robots and how robots can fundamentally change the future. We explore in particular what this means for the biomanufacturing industry.

Highlights include:

• Where do humanoids fit in pharma?
• What makes robotic adoption difficult (yet inevitable)?
• What could a future filled with humanoids could look like?

This episode breaks down what the robotic future might actually look like, and how close we are to building it!

New to Cell Mates? We're the podcast where pharma, robotics, and automation collide to reimagine the future of medicine—one operation at a time.

What happens when scientists and engineers collaborate to tackle the biggest challenges in pharma manufacturing? In this debut episode, Multiply Labs CEO Frederico Parietti, Ph.D., sits down with Sanket Acharya, Ph.D., Senior Director of Corporate Development at GenScript, to explore the critical intersection of science and automation.

Key topics we cover:
⚙️ What engineers often misunderstand about science
🔬 What scientists often get wrong about engineering
🤝 How cross-disciplinary collaboration drives innovation in pharma manufacturing
🤖 The role of automation and robotics in scaling personalized therapies

At Multiply Labs, we believe that automation is the future of pharma manufacturing—and that bridging the gap between disciplines is key to unlocking new breakthroughs. Cell Mates brings you candid conversations with industry leaders who are shaping the future of cell and gene therapy manufacturing.

🎧 Listen to the full episode now and join the conversation! Don’t forget to like, comment, and subscribe to stay updated on future episodes.

What’s the biggest difference between how scientists and engineers think? 🤔

What happens when you put scientists and engineers in the same room to brainstorm solutions to some of pharma’s biggest challenges? 

Multiply Labs explores these very questions and more in their NEW podcast: Cell Mates, the podcast that is building the future of pharma automation, one conversation at a time! 

🎧You won’t want to miss this…